Risperidone

Product NDC
13668-040
11-digit product format
136680040
Labeler code
13668
Product ID
13668-040_cd8bfb14-7054-4c69-b27f-8a960b5ecb5f
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Risperidone
Dosage form
TABLET
Route
ORAL
Labeler
Torrent Pharmaceuticals Limited
Application
ANDA079088
Marketing category
ANDA
Marketing start
2009-01-01
Substance
RISPERIDONE
Active strength
4 mg/1
Pharmacologic classes
Atypical Antipsychotic [EPC]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A079088-001RISPERIDONERISPERIDONE0.25MGTABLET / ORALAB2008-10-30
A079088-002RISPERIDONERISPERIDONE0.5MGTABLET / ORALAB2008-10-30
A079088-003RISPERIDONERISPERIDONE1MGTABLET / ORALAB2008-10-30
A079088-004RISPERIDONERISPERIDONE2MGTABLET / ORALAB2008-10-30
A079088-005RISPERIDONERISPERIDONE3MGTABLET / ORALAB2008-10-30
A079088-006RISPERIDONERISPERIDONE4MGTABLET / ORALAB2008-10-30

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A079088-001AB
A079088-002AB
A079088-003AB
A079088-004AB
A079088-005AB
A079088-006AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RisperidoneRISPERIDONETorrent Pharmaceuticals Limiteda6347895-5f16-43b4-92a0-b9904ac819372026-03-03Boxed warning, Warnings, Adverse reactionsExact identifier

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

boxed warning

WARNING : INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for use in patients with dementia-related psychosis. ( 5.1 ) Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions ( 5.1 )]

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Cerebrovascular events, including stroke, in elderly patients with dementia- related psychosis: Risperidone is not approved for use in patients with dementia-related psychosis. ( 5.2 ) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of risperidone and close monitoring. ( 5.3 ) Tardive dyskinesia: Consider discontinuing risperidone if clinically indicated. ( 5.4 ) Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. ( 5.5 ) o Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. ( 5.5 ) o Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. ( 5.5 ) o Weight Gain: Significant weight gain has been reported. Monitor weight gain. ( 5.5 ) Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration. ( 5.6 ) Orthostatic hypotension: For patients at risk, consider a lower starting dose and slower titration. ( 5.7 ) Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts in patients with a history of clinically significant low white blood cell count (WBC). Consider discontinuing risperidone if a clinically significant decline in WBC occurs in the absence of other causative factors. ( 5.9 ) Potential for cognitive and motor impairment: Use caution when operating machinery. ( 5.10 ) Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. ( 5.11 ) 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks),largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6%...

warnings and cautions table

Table 2. Change in Random Glucose from Seven Placebo-Controlled, 3- to 8- Week, Fixed- or Flexible-Dose Studies in Adult Subjects with Schizophrenia or Bipolar Mania RisperidonePlacebo1 to 8 mg/day>8 to 16 mg/day Mean change from baseline (mg/dL) n=555 n=748 n=164Serum Glucose-1.40.80.6 Proportion of patients with shiftsSerum Glucose(<140 mg/dL to ≥ 200 mg/dL)0.6%0.4%0%(3/525)(3/702)(0/158)

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions in clinical trials (≥5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-800-912-9561 or FDA at 1-800-FDA-1088, or www.fda.gov/medwatch The following are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 )] Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions ( 5.2 )] Neuroleptic malignant syndrome [see Warnings and Precautions ( 5.3 )] Tardive dyskinesia [see Warnings and Precautions ( 5.4 )] Metabolic Changes (Hyperglycemia and diabetes mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions ( 5.5 )] Hyperprolactinemia [see Warnings and Precautions ( 5.6 )] Orthostatic hypotension [see Warnings and Precautions ( 5.7 )] Falls [see Warnings and Precautions ( 5.8 )] Leukopenia, neutropenia, and agranulocytosis [see Warnings and Precautions ( 5.9 )] Potential for cognitive and motor impairment [see Warnings and Precautions ( 5.10 )] Seizures [see Warnings and Precautions ( 5.11 )] Dysphagia [see Warnings and Precautions ( 5.12 )] Priapism [see Warnings and Precautions ( 5.13 )] Disruption of body temperature regulation [see Warnings and Precautions ( 5.14 )] The most common adverse reactions in clinical trials (>5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in >1% of adults and/or >2% of pediatrics...

adverse reactions table

Table 8. Adverse Reactions in ≥2% of Risperidone -Treated Adult Patients (and greater than placebo) with Schizophrenia in Double-Blind, Placebo-Controlled Trials* Parkinsonism includes extrapyramidal disorder, musculoskeletal stiffness, parkinsonism, cogwheel rigidity, akinesia, bradykinesia, hypokinesia, masked facies, muscle rigidity, and Parkinson's disease. Akathisia includes akathisia and restlessness. Dystonia includes dystonia, muscle spasms, muscle contractions involuntary, muscle contracture, oculogyration, tongue paralysis. Tremor includes tremor and parkinsonian rest tremor.Percentage of Patients Reporting Reaction RisperidoneSystem/Organ Class Adverse Reaction2 to 8 mg per day (N=366)>8 to 16 mg per day (N=198)Placebo (N=225)Cardiac DisordersTachycardia130Eye DisordersVision blurred311Gastrointestinal DisordersNausea944Constipation896Dyspepsia865Dry mouth401Abdominal discomfort311Salivary hypersecretion21<1Diarrhea211General DisordersFatigue310Chest pain221Asthenia21<1Infections and InfestationsNasopharyngitis343Upper respiratory tract infection231Sinusitis121Urinary tract infection130InvestigationsBlood creatine phosphokinase increased12<1Heart rate increased<120Musculoskeletal and Connective Tissue DisordersBack pain411Arthralgia23<1Pain in extremity211Nervous System DisordersParkinsonism*14178Akathisia*10103Sedation1052Dizziness742Dystonia*342Tremor*231Dizziness postural200Psychiatric DisordersInsomnia322527Anxiety161111Respiratory, Thoracic and Mediastinal DisordersNasal congestion462Dyspnea120Epistaxis<120Skin and Subcutaneous Tissue DisordersRash141Dry skin130Vascular DisordersOrthostatic hypotension210

Additional Listing Data#

Finished product
Yes
Brand name base
Risperidone
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
RISPERIDONE4 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
UniiL6UH7ZF8HC
Rxcui312828, 312829, 312830, 312831, 312832, 314211

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6ab2126a-0ca2-c16c-ab6d-b3a031ba7ac6Product name520250303
0efa9fd6-2fb6-4cd3-8b0f-2a2bf9c4a09eProduct name120250128
e457a910-2c3a-4bfd-90b9-0310982c50ddProduct name120241218
42b1a2d5-888a-4386-ab9f-0979e0d7b4aaProduct name120231010
66685e90-862d-4873-a0c5-2be73b803c36Product name120230921
92d220a1-2a4c-4393-9080-7335ca8223ccProduct name120230823

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
13668-040-01Risperidone100 in 1 BOTTLETABLET10025
13668-040-05Risperidone500 in 1 BOTTLETABLET50025
13668-040-57Risperidone2100 in 1 BOTTLETABLET210025
13668-040-60Risperidone60 in 1 BOTTLETABLET6025
13668-040-64Risperidone90 in 1 CARTONTABLET9025

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
13668-040-01EA - Each13668-040e3045e05-c231-431b-97de-0813b443381f12012-07-24
13668-040-05EA - Each13668-040e2864cf1-b320-44bf-9587-3ab5e1fe554d12012-07-24
13668-040-60EA - Each13668-0401ba81791-0790-4212-be86-de1873d7e96212012-07-24
13668-040-64EA - Each13668-0409ccf8a3c-69dd-4d62-aa3f-ccb096e062c312012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
RISPERIDONEACTIVE INGREDIENTL6UH7ZF8HCRISPERIDONE TABLET [TORRENT PHARMACEUTICALS LIMITED]12
RISPERIDONEACTIVE MOIETYL6UH7ZF8HCRISPERIDONE TABLET [TORRENT PHARMACEUTICALS LIMITED]12
RISPERIDONEACTIVE INGREDIENTL6UH7ZF8HCRISPERIDONE TABLET [STATE OF FLORIDA DOH CENTRAL PHARMACY]1
RISPERIDONEACTIVE INGREDIENTL6UH7ZF8HCRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
RISPERIDONEACTIVE MOIETYL6UH7ZF8HCRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
RISPERIDONEACTIVE MOIETYL6UH7ZF8HCRISPERIDONE TABLET [STATE OF FLORIDA DOH CENTRAL PHARMACY]1
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61URISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
FD&C BLUE NO. 2INACTIVE INGREDIENTL06K8R7DQKRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
FD&C YELLOW NO. 6INACTIVE INGREDIENTH77VEI93A8RISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
FERRIC OXIDE REDINACTIVE INGREDIENT1K09F3G675RISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
FERRIC OXIDE YELLOWINACTIVE INGREDIENTEX438O2MRTRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
HYPROMELLOSE 2208 (100 MPA.S)INACTIVE INGREDIENTB1QE5P712KRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
LACTOSEINACTIVE INGREDIENTJ2B2A4N98GRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I30RISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
POLYETHYLENE GLYCOL 400INACTIVE INGREDIENTB697894SGQRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU4RISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
SODIUM STARCH GLYCOLATE TYPE A POTATOINACTIVE INGREDIENT5856J3G2A2RISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
STARCH, CORNINACTIVE INGREDIENTO8232NY3SJRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
STARCH, POTATOINACTIVE INGREDIENT8I089SAH3TRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
TALCINACTIVE INGREDIENT7SEV7J4R1URISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JPRISPERIDONE TABLET [MAJOR PHARMACEUTICALS]1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
13668-040RISPERIDONE TABLET [TORRENT PHARMACEUTICALS LIMITED]24Current NDC, Legacy NDC, 5 package rows20250227_a6347895-5f16-43b4-92a0-b9904ac81937.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
312828risperiDONE 0.25 MG Oral TabletPSNa6347895-5f16-43b4-92a0-b9904ac8193725
312829risperiDONE 0.5 MG Oral TabletPSNa6347895-5f16-43b4-92a0-b9904ac8193725
312830risperiDONE 1 MG Oral TabletPSNa6347895-5f16-43b4-92a0-b9904ac8193725
312831risperiDONE 2 MG Oral TabletPSNa6347895-5f16-43b4-92a0-b9904ac8193725
312832risperiDONE 3 MG Oral TabletPSNa6347895-5f16-43b4-92a0-b9904ac8193725
314211risperiDONE 4 MG Oral TabletPSNa6347895-5f16-43b4-92a0-b9904ac8193725
312828risperidone 0.25 MG Oral TabletSCDa6347895-5f16-43b4-92a0-b9904ac8193725
312829risperidone 0.5 MG Oral TabletSCDa6347895-5f16-43b4-92a0-b9904ac8193725
312830risperidone 1 MG Oral TabletSCDa6347895-5f16-43b4-92a0-b9904ac8193725
312831risperidone 2 MG Oral TabletSCDa6347895-5f16-43b4-92a0-b9904ac8193725
312832risperidone 3 MG Oral TabletSCDa6347895-5f16-43b4-92a0-b9904ac8193725
314211risperidone 4 MG Oral TabletSCDa6347895-5f16-43b4-92a0-b9904ac8193725
312830risperiDONE 1 MG Oral TabletPSNdce4437a-bf43-483c-8db2-5eb58fa8a5591
312831risperiDONE 2 MG Oral TabletPSNdce4437a-bf43-483c-8db2-5eb58fa8a5591
312832risperiDONE 3 MG Oral TabletPSNdce4437a-bf43-483c-8db2-5eb58fa8a5591
314211risperiDONE 4 MG Oral TabletPSNdce4437a-bf43-483c-8db2-5eb58fa8a5591
312830risperidone 1 MG Oral TabletSCDdce4437a-bf43-483c-8db2-5eb58fa8a5591
312831risperidone 2 MG Oral TabletSCDdce4437a-bf43-483c-8db2-5eb58fa8a5591
312832risperidone 3 MG Oral TabletSCDdce4437a-bf43-483c-8db2-5eb58fa8a5591
314211risperidone 4 MG Oral TabletSCDdce4437a-bf43-483c-8db2-5eb58fa8a5591

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
13668-040-0113668004001100 TABLET in 1 BOTTLE (13668-040-01) 100 tablet2009-01-010000-00-00NoNoCurrent
13668-040-0513668004005500 TABLET in 1 BOTTLE (13668-040-05) 500 tablet2009-01-010000-00-00NoNoCurrent
13668-040-57136680040572100 TABLET in 1 BOTTLE (13668-040-57) 2100 tablet2009-01-010000-00-00NoNoCurrent
13668-040-601366800406060 TABLET in 1 BOTTLE (13668-040-60) 60 tablet2009-01-010000-00-00NoNoCurrent
13668-040-641366800406490 TABLET in 1 CARTON (13668-040-64) 90 tablet2009-01-010000-00-00NoNoCurrent